Hyperforin is best suited for the treatment of acute myeloid leukaemia (AML) and chronic lymphoid leukaemia (CLL), triggering apoptosis through the modulation of the PI3K/Akt signaling pathway, where it destroys the kinase activity of serine/threonine protein kinase B (PKB)/Akt1 and thereby encourages the activation of proapoptotic Bad and procaspases-9/-3. The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.